| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.12. | Vertex Pharmaceuticals Incorporated: Vertex Presents Positive Long-Term Data On CASGEVY (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update | 451 | Business Wire | - Data from long-term follow-up of patients in clinical trials further demonstrate durability of the transformative benefits of CASGEVY -
Safety profile consistent with busulfan conditioning and... ► Artikel lesen | |
| 08.12. | Genmab A/S: Investigational Epcoritamab (DuoBody CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis | 447 | Business Wire | Genmab A/S (Nasdaq: GMAB):
Preliminary analyses from the EPCORECLL-1 trial demonstrates overall response rate (ORR) of 61 percent and complete response (CR) rate of 39 percent in heavily pretreated... ► Artikel lesen | |
| 08.12. | Genmab A/S: Investigational Epcoritamab (DuoBody CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) | 696 | Business Wire | Genmab A/S (Nasdaq: GMAB):
Results show 96 percent overall response rate (ORR), 87 percent complete response (CR), and 80 percent 21-month progression-free survival (PFS) in patients with... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| NOVO NORDISK | 1.082 |
| TUI | 697 |
| BAYER | 651 |
| TESLA | 639 |
| EVOTEC | 633 |
| NVIDIA | 632 |
| VOLKSWAGEN | 578 |
| NEL | 384 |
| BYD | 376 |
| PALANTIR TECHNOLOGIES | 376 |
| MICROSTRATEGY | 332 |
| RHEINMETALL | 323 |
| SUPER MICRO COMPUTER | 323 |
| RWE | 261 |
| D-WAVE QUANTUM | 259 |
| PLUG POWER | 233 |
| RENK GROUP | 231 |
| ATOS | 230 |
| BASF | 224 |
| MANZ | 218 |
| COMMERZBANK | 215 |
| ALLIANZ | 204 |
| DEFI TECHNOLOGIES | 203 |
| DEUTSCHE BANK | 203 |
| TEAMVIEWER | 194 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
